Profile
| Metric | Value |
|---|---|
| Full Name | Novo Nordisk A/S |
| Ticker | NYSE: NVO |
| Exchange | NYSE |
| Sector | Healthcare |
| Industry | General Drug Manufacturers |
| Country | Denmark |
| IPO | |
| Indexes | Not included |
| Website | novonordisk.com |
| Employees | 77,406 |
Key Metrics
| Metric | Date | Value |
|---|---|---|
| Price | $62.01 | |
| Price, 1D Change | +4.53% | |
| Market Cap | $276B | |
| TTM Dividend Yield | 2.79% | |
| PE Ratio | 18.06 | |
| Beta | 0.87 | |
| Revenue | $42B | |
| Revenue, 1Y Change | +24.97% | |
| EPS | $3.28 | |
| EPS, 1Y Change | +21.47% |
Chart
Add series to chart(max: 6)
Series
SUGGESTED SERIES
Events
| Metric | Date | Value |
|---|---|---|
| Next Earnings | ||
| Last Qtr. Earnings | ||
| Last Ann. Earnings | ||
| Last Ex-Dividend | $0.58 | |
| Next Ex-Dividend | N/A | N/A |
| Last Split | 2:1 | |
| Next Split | N/A | N/A |
| Last Ticker Change | N/A | N/A |
| Next Ticker Change | N/A | N/A |
🔒 Log In To Unlock Full Data
Estimates
| Metric | Date | Value |
|---|---|---|
| EPS | $3.28 | |
| EPS Estimate | $23.15 | |
| EPS Est. Change | +605.32% | |
| Revenue | $42.12B | |
| Revenue Estimate | $307.57B | |
| Revenue Est. Change | +630.31% | |
| Current Price | $62.01 | |
| Price Target | - | - |
| Price Tgt. Change | - | - |
🔒 Log In To Unlock Full Data
EPS
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $2.61 | $2.70 | +3.50% | |
| $22.86 | $3.28 | -85.64% | |
| $23.15 | N/A | +605.32% | |
| $22.47 | N/A | +584.61% |
Revenue
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $33.15B | $33.70B | +1.67% | |
| $287.76B | $42.12B | -85.36% | |
| $307.57B | N/A | +630.31% | |
| $305.22B | N/A | +624.73% |
🔒 Log In To Unlock Full Data
Performance
| Metric | Date | Value |
|---|---|---|
| Price, 1Y | -23.04% | |
| Price, 3Y | -12.10% | |
| Market Cap, 1Y | -22.98% | |
| Market Cap, 3Y | -13.18% | |
| Revenue, 1Y | +24.97% | |
| Revenue, 3Y | +88.20% | |
| EPS, 1Y | +21.47% | |
| EPS, 3Y | +99.14% |
🔒 Log In To Unlock Full Data
Technical Indicators
| Metric | Date | Value |
|---|---|---|
| Current Price | $62.01 | |
| SMA 200 | $58.94 | |
| SMA 200 vs Price | -4.96% | |
| SMA 50 | $51.12 | |
| SMA 50 vs Price | -17.56% | |
| Beta | 0.87 | |
| ATR | $2.14 | |
| 14-Day RSI | 61.91 | |
| 10-Day Volatility | 56.64% | |
| 1-Year Volatility | 49.86% |
Dividends
| Metric | Date | Value |
|---|---|---|
| Last Paid | $0.58 | |
| Upcoming | N/A | N/A |
| Dividend Yield | 2.33% | |
| Total Dividend | $1.45 | |
| Dividends Paid | $6.40B | |
| Payout Ratio | 43.71% |
🔒 Log In To Unlock Full Data
Income & Profitability
| Metric | Date | Value |
|---|---|---|
| Revenue | $42.12B | |
| EPS | $3.28 | |
| Gross Profit | $35.31B | |
| Gross Margin | 83.85% | |
| Operating Profit | $20.22B | |
| Operating Margin | 31.85% | |
| Net Income | $14.65B | |
| Net Margin | 34.78% | |
| EBITDA | $21.46B |
🔒 Log In To Unlock Full Data
Financial Health
| Metric | Date | Value |
|---|---|---|
| Debt To Equity | 0.72 | |
| Current Ratio | 0.74 | |
| Quick Ratio | 0.55 | |
| - | ||
| F-Score | 5 | |
| Altman Z-Score | 5.66 |
Valuations
| Metric | Date | Value |
|---|---|---|
| PE Ratio | 18.06 | |
| PS Ratio | 5.90 | |
| PB Ratio | 13.59 | |
| EV/EBITDA | 12.43 | |
| Enterprise Value | N/A | - |
Balance Sheet
| Metric | Date | Value |
|---|---|---|
| Book Value | $15.10B | |
| Cash & Equivalents | $3.65B | |
| Total Assets | $64.68B | |
| Current Assets | $22.34B | |
| Total Liabilities | $44.76B | |
| Current Liabilities | $30.21B | |
| Total Debt | $14.27B | |
| Short Term Debt | $1.82B | |
| Accounts Payable | $4.01B |
Expenses
| Metric | Date | Value |
|---|---|---|
| Total Expenses | $27.47B | |
| Operating Expenses | $15.10B | |
| Cost Of Goods Sold | $6.80B | |
| SG&A | $0.00 | |
| D&A | $1.24B | |
| Interest Expense | $0.00 | |
| Income Tax | $3.80B |
Cash Flow
| Metric | Date | Value |
|---|---|---|
| CFO | $17.54B | |
| CFI | -$18.69B | |
| CFF | $1.27B | |
| Capex | $7.44B | |
| Free Cash Flow | $10.10B |
Recent analyst updates
| Metric | Date | Value |
|---|---|---|
| CICC | ||
| Argus Research | → | |
| Goldman Sachs | → | |
| BMO Capital | → | |
| HSBC | → | |
| BMO Capital | → | |
| HSBC | → | |
| Morgan Stanley | → | |
| Berenberg | → | |
| TD Cowen | → |
Analyst sentiment
Institutional ownership
Screeners with NVO
FAQ
What is the ticker symbol for Novo Nordisk A/S?
The ticker symbol for Novo Nordisk A/S is NYSE:NVO
Does Novo Nordisk A/S pay dividends?
Yes, Novo Nordisk A/S pays dividends. The last payment was $0.58, with an ex-dividend date on August 18, 2025
What sector is Novo Nordisk A/S in?
Novo Nordisk A/S is in the Healthcare sector
What industry is Novo Nordisk A/S in?
Novo Nordisk A/S is in the General Drug Manufacturers industry
What country is Novo Nordisk A/S based in?
Novo Nordisk A/S is headquartered in Denmark
When did Novo Nordisk A/S go public?
Novo Nordisk A/S initial public offering (IPO) was on April 30, 1981
Is Novo Nordisk A/S in the S&P 500?
No, Novo Nordisk A/S is not included in the S&P 500 index
Is Novo Nordisk A/S in the NASDAQ 100?
No, Novo Nordisk A/S is not included in the NASDAQ 100 index
Is Novo Nordisk A/S in the Dow Jones?
No, Novo Nordisk A/S is not included in the Dow Jones index
When was Novo Nordisk A/S last earnings report?
Novo Nordisk A/S's most recent earnings report was on November 5, 2025
When does Novo Nordisk A/S report earnings?
The next expected earnings date for Novo Nordisk A/S is February 4, 2026
Data Sources & References
- NVO Official Website www.novonordisk.com
- Most Recent Quarterly Report (10-Q) www.sec.gov/Archives/edgar/data/353278/000035327825000005/0000353278-25-000005-index.htm
- Most Recent Annual Report (10-K) www.sec.gov/Archives/edgar/data/353278/000162828025003920/0001628280-25-003920-index.htm
- NVO Profile on Yahoo Finance finance.yahoo.com/quote/NVO
- NVO Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/nvo